Analysis of Klotho Protein Level in Patients with Myocardial Infarction and Concurrent Chronic Obstructive Pulmonary Disease with Different Manifestations

The objective: to compare the level of Klotho protein in patients with myocardial infarction (M I) and concurrent chronic obstructive pulmonary disease (COPD) and patients with COPD only with consideration of specific manifestations of COPD (severity of symptoms and risk of exacerbations). Subjects and Methods. 144 patients were examined and divided into the following groups: MI + COPD Group - patients with MI and concurrent COPD (60 patients), COPD Group - patients with COPD (54 patients) and HI Group - somatically healthy individuals (30 people). The patients were divided into subgroups (A, B, C, D) according to the GOLD 2019 classification. Enzyme immunoassay was used to test the level of Klotho. Results. A statistically significant lower level of Klotho was detected in patients in MI + COPD Group compared to COPD Group and healthy individuals. Patients in the subgroups with severe symptoms (B and D) in both the COPD and MI + COPD Groups had statistically significantly lower levels of Klotho compared to those in the subgroups with no symptoms (A and C). Among patients with MI + COPD in subgroups A, B, C, D, the Kloto level was statistically significantly lower versus the patients of the corresponding subgroups in COPD Group. The lowest level of Klotho was detected in MI + COPD and COPD Groups in patients of subgroup D, that was in patients with severe symptoms and frequent exacerbations of COPD. The data obtained were confirmed by correlation analysis results. It was found that in MI + COPD and COPD Groups, the level of Klotho had a negative correlation with both the severity of symptoms and number of COPD exacerbations. Correlations were the strongest between the level of Klotho and parameters characterizing the severity of COPD symptoms.